© 2026 WEKU
Lexington's Choice for NPR
Play Live Radio
Next Up:
0:00
0:00
0:00 0:00
Available On Air Stations
The 1850 campaign is replacing lost federal funds one supporter at a time. Thanks to our listeners and supporters, we are now just 141 away from reaching this goal of 1850 new supporters donating at least $10 a month. Click here to join the campaign!

High-Strength Infant Meds With Acetaminophen To Be Dropped

iStockphoto.com

Makers of over-the-counter medicines for kids have agreed to stop producing infant-only liquid painkillers containing concentrated acetaminophen.

Some painkilling drops for infants contain as much as 80 milligrams of acetaminophen per milliliter. Acetaminophen liquids for older children typically contain 32 milligrams per milliliter.

Parents can wind up giving children too much acetaminophen by using the infant-strength drops in large quantities. Soon only the lower-strength version will be available — 160 milligrams of acetaminophen per 5 milliliters. (A teaspoon is about 5 milliliters.)

The Wall Street Journal, which first reported on the change, said there were 14 hospitalizations caused by pediatric versions of medicines containing acetaminophen in 2009, citing data from the American Association of Poison Control Centers.

The Consumer Healthcare Products Association, a trade group for makers of OTC medicines, said in a statement that the voluntary change will make it easier for parents and caregivers to use the right dose of medicine. The shift to a uniform strength of acetaminophen will begin by the middle of this year, the group's statement said.

How much medicine to use depends on a child's age. Consult the instructions on each medicine to be sure.

And check the ingredients, too. As a recent study found, most people didn't know which active ingredient was in their preferred painkiller.

Copyright 2021 NPR. To see more, visit https://www.npr.org.

Scott Hensley edits stories about health, biomedical research and pharmaceuticals for NPR's Science desk. During the COVID-19 pandemic, he has led the desk's reporting on the development of vaccines against the coronavirus.
WEKU depends on support from those who view and listen to our content. There's no paywall here. Please support WEKU with your donation.
Related Content